Core Viewpoint - A class action securities lawsuit has been filed against Cytokinetics, alleging securities fraud related to misleading statements about the New Drug Application (NDA) for aficamten, which may have led to significant investor losses [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for Cytokinetics investors affected by alleged securities fraud between December 27, 2023, and May 6, 2025 [1]. - Defendants allegedly made materially false statements regarding the expected approval timeline for the NDA for aficamten, claiming approval from the FDA in the second half of 2025 based on a September 26, 2025 PDUFA date [2]. - The complaint highlights that the company failed to disclose risks related to not submitting a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [2]. - During an earnings call on May 6, 2025, it was revealed that the company had discussions with the FDA about safety monitoring but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [2]. Group 2: Next Steps for Investors - Investors who suffered losses in Cytokinetics during the relevant timeframe have until November 17, 2025, to request the Court to appoint them as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, alleging misleading statements regarding its financial health and growth prospects, particularly following a significant stock price decline after its earnings report in August 2025 [1][4]. Summary by Relevant Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., covers the period from May 7, 2025, to August 5, 2025, claiming that LifeMD made false statements, especially on May 6, 2025, when it reported first-quarter results and raised its full-year revenue and adjusted EBITDA guidance [2]. - The complaint asserts that LifeMD's optimistic outlook regarding its competitive position in virtual obesity care and performance from its RexMD brand was misleading, as it did not disclose significant operational challenges [2][3]. Financial Performance and Stock Impact - LifeMD's stock price fell over 44% the day after the company announced its second-quarter results on August 5, 2025, which missed revenue and earnings per share estimates and included a reduction in full-year guidance [4]. - During the earnings call, management attributed the poor performance to "temporary elevated customer acquisition costs" in the RexMD business and issues with patient refunds in its weight management offerings [4]. Investor Actions - Investors who suffered losses during the specified period are encouraged to participate in the lawsuit as a means to recover damages [5]. - Hagens Berman, the law firm leading the investigation, is looking into whether LifeMD was aware of but failed to disclose key operational problems [6].

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements regarding the safety and functionality of its Novum IQ Large Volume Pump [1][3]. Summary by Sections Class Action Lawsuit Details - The class action lawsuit is titled "Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc." and covers investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025 [1]. - Investors have until December 15, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. Allegations Against Baxter - The lawsuit alleges that Baxter's Novum IQ Large Volume Pump had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [3]. - Baxter was reportedly aware of multiple device malfunctions and injuries but failed to take adequate remedial measures [3]. - On July 31, 2025, Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, which led to a more than 22% drop in the company's stock price [4]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during the class period to seek appointment as lead plaintiff [5]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [5]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7].

Core Viewpoint - Rosen Law Firm is reminding investors who bought or sold common stock of Cepton, Inc. (NASDAQ: CPTN) during the Class Period from July 29, 2024, to January 6, 2025, about the December 8, 2025, deadline to become a lead plaintiff in a class action lawsuit [1][2]. Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lead plaintiff must file a motion with the Court by December 8, 2025, to represent other class members [3]. Group 2: Case Allegations - The lawsuit alleges that Cepton's management made materially false and misleading statements regarding the company's business and operations [5]. - Specific allegations include that Cepton received a credible third-party bid valuing the company at more than double the Koito Acquisition, which was not disclosed to shareholders [5]. - The Board of Directors allegedly failed to explore this offer meaningfully and did not disclose its terms, depriving shareholders of the opportunity to consider the acquisition [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [4].

Core Viewpoint - The Baxter International, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the safety and functionality of its Novum IQ Large Volume Pump, which reportedly has systemic defects that pose serious risks to patients [3][4]. Summary by Sections Class Action Lawsuit Details - The lawsuit is titled Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., and covers purchasers of Baxter common stock from February 23, 2022, to July 30, 2025 [1]. - Investors have until December 15, 2025, to seek appointment as lead plaintiff in the class action [1]. Allegations Against Baxter - Baxter allegedly made false or misleading statements and failed to disclose significant issues with the Novum IQ LVP, including systemic defects leading to malfunctions such as underinfusion and overinfusion [3]. - The company was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - Baxter's attempts to address these issues were deemed inadequate, as design flaws persisted, continuing to harm patients [3]. Impact on Stock Price - Following Baxter's announcement on July 31, 2025, to pause shipments and installations of the Novum LVP, the company's stock price fell by more than 22% [4]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during the class period to seek lead plaintiff status, which involves directing the lawsuit on behalf of all class members [5]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Points - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between January 16, 2025, and September 12, 2025 [1] - The lawsuit claims that aTyr misled investors regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage [2] - Following the announcement that the EFZO-FIT study did not meet its primary endpoint, aTyr's stock price plummeted by 83.2%, from $6.03 to $1.02 per share in one day [2] Case Details - The complaint alleges that the defendants made positive statements while concealing material adverse facts about the drug's efficacy [2] - The primary endpoint not being met was disclosed during an investor call on September 15, 2025, leading to significant stock price decline [2] - aTyr plans to engage with the FDA to determine the next steps after the disappointing study results [2] Next Steps - Investors who suffered losses during the relevant timeframe have until December 8, 2025, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years [4]

Core Viewpoint - Tronox Holdings plc is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between February 12, 2025, and July 30, 2025 [1][2] Company Performance - The lawsuit claims that Tronox provided overly positive statements while concealing material adverse facts about its commercial division and forecasting processes, which ultimately led to declining sales and increased costs [2] - On July 30, 2025, Tronox reported a significant reduction in TiO2 sales for the second quarter, attributing the decline to a softer coatings season and heightened competition [2] - Following the announcement, Tronox revised its 2025 financial outlook, lowering full-year revenue guidance and reducing its dividend by 60% [2] - The stock price of Tronox plummeted from $5.14 per share on July 30, 2025, to $3.19 per share on July 31, 2025, marking a decline of approximately 38% in one day [2] Legal Proceedings - Investors who suffered losses during the specified timeframe have until November 3, 2025, to request to be appointed as lead plaintiff in the lawsuit [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - A class action securities lawsuit has been filed against Fortinet, Inc. for alleged securities fraud affecting investors between November 8, 2024, and August 6, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Fortinet's management made false statements regarding the refresh cycle of their products, suggesting it would be more profitable than it actually was [2]. - It is alleged that the refresh cycle consisted of old products that represented only a "small percentage" of Fortinet's overall business [2]. - The complaint also states that Fortinet misrepresented the number of FortiGate firewalls available for upgrade and that the refresh momentum was overstated, with only half of the refresh completed by the end of Q2 2025 [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until November 21, 2025, to request appointment as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Snap Inc. for alleged securities fraud affecting investors between April 29, 2025, and August 5, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Snap provided misleading positive statements while concealing significant declines in advertising revenue growth, which fell from 9% in Q1 to only 1% in April 2025 [2]. - Following the announcement of second-quarter financial results on August 5, 2025, Snap reported a deceleration in advertising revenue growth, attributing it to issues with their ad platform and other factors [2]. - Snap's stock price dropped from $9.39 per share on August 5, 2025, to $7.78 per share on August 6, 2025, marking a decline of approximately 17.15% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 20, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Fluor Corporation, alleging securities fraud that negatively impacted investors between February 18, 2025, and July 31, 2025 [1][2] Group 1: Allegations of Fraud - The lawsuit claims that Fluor Corporation made false statements regarding the costs associated with its infrastructure projects, which were increasing due to subcontractor design errors, price hikes, and scheduling delays [2] - It is alleged that these issues, along with reduced capital spending from customers and economic uncertainty, were likely to have a significant negative impact on the Company's business and financial results [2] - The financial guidance provided by Fluor for FY 2025 is claimed to be unreliable and overstated regarding the effectiveness of its risk mitigation strategies and the impact of economic uncertainty [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until November 14, 2025, to request to be appointed as lead plaintiff in the lawsuit [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]